Abstract
Ifosfamide is commonly used as a chemotherapeutic agent in children. The authors report a 4-y-old boy who developed proximal renal tubulopathy with florid rickets a year after completion of ifosfamide therapy for Ewing's sarcoma. After initiation of treatment, there was complete healing of rickets and he did not need supplements beyond 18 mo. Growth monitoring and musculoskeletal system examination is important in all children who have received ifosfamide therapy. Routine monitoring for nephrotoxicity during and after ifosfamide therapy helps in early identification and intervention.
This is a preview of subscription content, log in via an institution to check access.
References
Klastersky J. Side effects of ifosfamide. Oncology. 2003;65:7–10.
Springate JE. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol. 1997;17:75–9.
Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 2003;41:190–7.
Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer. 2007;48:447–52.
Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, et al. Long-term evaluation of ifosfamide-related nephrotoxicity in children. J Clin Oncol. 2009;27:5350–5.
Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: A UKCCSG late effects group study. United Kingdom children’s cancer study group. Br J Cancer. 2000;82:1636–45.
McCune JS, Risler LJ, Phillips BR, Thummel KE, Blough D, Shen DD. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005;33:1074–81.
Rossi R, Pleyer J, Schafers P, Schäfers P, Kuhn N, Kleta R, et al. Development of ifosfamide induced nephrotoxicity: Prospective follow-up in 75 patients. Med Pediatr Oncol. 1999;32:177–82.
Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Glomerular toxicity persists 10 y after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatr Blood Cancer. 2010;54:983–9.
Contributions
GC, SM, APL, RRJ were involved in the diagnosis and case management. APL reviewed literature and prepared the initial draft. SM, APL, GC prepared the final manuscript.
Conflict of Interest
None.
Role of Funding Source
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lionel, A.P., Chinnaswamy, G., John, R.R. et al. Ifosfamide Induced Renal Rickets. Indian J Pediatr 81, 943–945 (2014). https://doi.org/10.1007/s12098-013-1112-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-013-1112-x